Ogonczyk-Makowska, Daniela
Brun, Pauline http://orcid.org/0000-0003-0762-832X
Vacher, Clémence
Chupin, Caroline http://orcid.org/0000-0003-3860-3475
Droillard, Clément
Carbonneau, Julie
Laurent, Emilie
Dulière, Victoria
Traversier, Aurélien
Terrier, Olivier http://orcid.org/0000-0001-9393-7684
Julien, Thomas
Galloux, Marie http://orcid.org/0000-0001-7477-8489
Paul, Stéphane http://orcid.org/0000-0002-8830-4273
Eléouët, Jean-François
Fouret, Julien
Hamelin, Marie-Eve
Pizzorno, Andrés http://orcid.org/0000-0002-0918-6804
Boivin, Guy
Rosa-Calatrava, Manuel
Dubois, Julia http://orcid.org/0000-0002-9777-2968
Funding for this research was provided by:
Association Nationale de la Recherche et de la Technologie (2020 0656)
Gouvernement du Canada | Canadian Institutes of Health Research (148361)
Agence Nationale de la Recherche (AAP19 Metavac-T17)
Article History
Received: 24 October 2023
Accepted: 31 May 2024
First Online: 19 June 2024
Competing interests
: Manuel Rosa-Calatrava, Guy Boivin, Julia Dubois, and Marie-Eve Hamelin are co-founders and shareholders of Vaxxel SAS. Andrés Pizzorno and Olivier Terrier are shareholders of Vaxxel SAS. Julia Dubois was the R&D project manager of Vaxxel SAS. Caroline Chupin is an employee of Vaxxel SAS. The other authors declare no competing interests. The authors declare the following patent : EP22305240.2 – PCT/EP2023/055221 concerning Vaccine composition against two respiratory viruses (Inventors: Daniela Ogonczyk-Makowska, Jean-François Eléouët, Guy Boivin, Julia Dubois and Manuel Rosa-Calatrava ; Applicants : Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Université Claude Bernard Lyon 1 (UCBL) Ecole Normale Supérieure de Lyon (ENS Lyon), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE) and Vaxxel SAS).